Zacks: Brokerages Set $26.75 Price Target for Verona Pharma PLC American Depositary Share (VRNA)

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have earned an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus price objective of $26.75 for the company, according to Zacks. Zacks has also assigned Verona Pharma PLC American Depositary Share an industry rank of 158 out of 265 based on the ratings given to its competitors.

Several research analysts recently issued reports on VRNA shares. Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Verona Pharma PLC American Depositary Share in a research report on Friday, September 8th. Zacks Investment Research upgraded shares of Verona Pharma PLC American Depositary Share from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th.

A number of institutional investors have recently added to or reduced their stakes in VRNA. FIL Ltd acquired a new position in Verona Pharma PLC American Depositary Share during the 2nd quarter valued at about $873,000. Tekla Capital Management LLC acquired a new position in Verona Pharma PLC American Depositary Share during the 2nd quarter valued at about $3,211,000. Finally, Vivo Capital LLC acquired a new position in Verona Pharma PLC American Depositary Share during the 2nd quarter valued at about $8,208,000. Institutional investors own 30.16% of the company’s stock.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) traded down 2.9809% during mid-day trading on Thursday, reaching $15.2805. 2,462 shares of the company traded hands. Verona Pharma PLC American Depositary Share has a 52-week low of $11.03 and a 52-week high of $17.50. The stock’s 50 day moving average is $14.44 and its 200 day moving average is $13.95. The stock’s market capitalization is $200.59 million.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.09). On average, analysts anticipate that Verona Pharma PLC American Depositary Share will post ($2.23) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://transcriptdaily.com/2017/10/08/zacks-brokerages-set-26-75-price-target-for-verona-pharma-plc-american-depositary-share-vrna.html.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply